Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: Multinational phase II-III trial results

Journal of Clinical Oncology

Volumn 19, Issue 9, 2001, Pages 2456-2471

  Duvic, M ^a   Hymes, K ^a   Heald, P ^a   Breneman, D ^a   Martin, A G ^a   Myskowski, P ^a   Crowley, C ^a   Yocum, R C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; RETINOID X RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DEFECT; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 0035340844     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.9.2456     Document Type: Article

References (58)

1. The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States
2. Extranodal hematopoietic/lymphoid disorders
3. Cutaneous lymphomas other than MF
4. Mycosis fungoides and Sézary syndrome
5. Association of erythrodermic cutaneous T cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vb gene expansion
6. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma
7. Transformation of mycosis fungoides/Sézary syndrome: Clinical characteristics and prognosis
8. Demonstration of frequent occurrence of clonal T-cells in the peripheral blood of patients with primary cutaneous T cell lymphoma
9. Detection of clonal T-cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoides/ Sézary syndrome
10. Transformation of mycosis fungoides: T-cell receptor beta gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30+ large-cell lymphoma
11. Prognosis and staging of cutaneous T cell lymphoma
12. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides
13. Prognosis in cutaneous T-cell lymphoma by skin stage: Long term survival in 489 patients
14. Mycosis fungoides and the Sézary syndrome
15. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides
16. Advances in the management of cutaneous T-cell lymphoma
17. Emerging therapies in CTCL
18. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
19. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells
20. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma
21. Infections complicating mycosis fungoides and Sézary syndrome
22. Septicemic complications of the cutaneous T cell lymphomas
23. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids
24. Measuring the quality of life of cancer patients: A concise QL-index for use by physicians
25. The importance of understanding sample preparation
26. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069
27. A Phase I study of LGD1069 in adults with advanced cancer
28. Oral Targretin (bexarotene) capsules are safe and effective in refractory or persistent early stage cutaneous T-cell lymphoma: Results of the phase 2-3 clinical trial
29. Treatment of cutaneous T cell lymphoma with retinoids
30. Treatment of cutaneous T cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid
31. Isotretinoin in cutaneous T cell lymphoma
32. 13-cis-retinoic acid effective in mycosis fungoides: A report from the Scandinavian mycosis fungoides group
33. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma
34. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)
35. Treatment of mycosis fungoides with isotretinoin
36. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298
37. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells
38. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids
39. Combined modality therapy for cutaneous T cell lymphoma
40. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate
41. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides
42. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage: A report from the Scandinavian Mycosis Fungoides Group
43. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
44. 389IL-2 (ONTAK) cytotoxicity in human T-cells is modulated by retinoic acid
45. 389IL-2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma
46. 389IL-2) in lymphomas expressing the receptor for interleukin-2
47. 389-IL-2 (ONTAK) for the treatment of cutaneous T cell lymphoma
48. Drug treatment of lipid disorders
49. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease
50. Treatment of combined hyperlipidemia with fluvastatin and gemfibrizol, alone or in combination, does not induce muscle damage
51. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
52. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
53. The molecular and genetic dissection of the retinoid signaling pathway
54. Central hypothyroidism associated with retinoid X receptor-selective ligands
55. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
56. Herpes zoster-varicella in cutaneous T-cell lymphomas
57. Mycosis fungoides and the Sézary syndrome: A review of pathogenesis, diagnosis, and therapy
58. ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma - A 4-year follow-up study